Proteome Sciences PLC
PRM
Company Profile
Business description
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Contact
Downside Bridge Road
Coveham House
CobhamSurreyKT11 3EP
GBRT: +44 2070432116
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
32
Stocks News & Analysis
stocks
Avoid these overvalued ASX shares
The two shares with the highest price to fair value in our Australian coverage.
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Watching AI monetization, capex’s impact on margins, and guidance on Azure.
stocks
Lithium’s latest drop and what it means for ASX investors
Volatility returns to the lithium market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,001.80 | 11.60 | 0.13% |
| CAC 40 | 8,363.14 | 23.03 | 0.28% |
| DAX 40 | 25,011.35 | 164.66 | 0.66% |
| Dow JONES (US) | 52,224.64 | 385.38 | 0.74% |
| FTSE 100 | 10,585.91 | 61.15 | 0.58% |
| HKSE | 25,132.29 | 10.76 | -0.04% |
| NASDAQ | 25,837.21 | 329.13 | 1.29% |
| Nikkei 225 | 67,350.79 | 1,118.60 | 1.69% |
| NZX 50 Index | 13,686.02 | 29.99 | 0.22% |
| S&P 500 | 7,509.20 | 65.92 | 0.89% |
| S&P/ASX 200 | 8,819.00 | 12.50 | 0.14% |
| SSE Composite Index | 3,863.90 | 0.47 | -0.01% |